Preview Mode Links will not work in preview mode

Impactful malaria science, and the trailblazers leading the fight. A podcast from the Johns Hopkins Malaria Research Institute.

Sep 17, 2021

We're used to thinking of vaccines for individual protection. But what about a malaria jab to protect the mosquito?


Finding antigens for a transmission-blocking vaccine to target is a tough job - only two have reached clinical trials. Though given to humans, these vaccines aim to disrupt the malaria lifecycle in the mosquito, and scientists have now found that Pf77 and male development gene 1 (PfMDV-1) could be potential candidates. In the lab, mice immunised with these antigens successfully developed antibodies against them. Researchers then isolated these antibodies from the mice and fed them to mosquitoes - along with malaria parasites - to test if they can inhibit parasite development. Indeed, they reduced the number of oocysts - the form of the parasite containing transmissible sporozoites - by up to 93%. And when researchers looked in Ghanaian adults naturally exposed to malaria, they found antibodies to these proteins, suggesting natural exposure could boost responses elicited by vaccination.

Plasmodium falciparum Pf77 and male development gene 1 as vaccine antigens that induce potent transmission-reducing antibodies

About The Podcast

The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and share with the global community.